Butbul Aviel Yonatan, Tatour Sameh, Gershoni Baruch Ruth, Brik Riva
Department of Pediatrics B, Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel; Pediatric Rheumatology Service, Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel; Rappaport Faculty of Medicine, Technion-lsrael Institute of Technology, Haifa, Israel.
Department of Pediatrics B, Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel; Rappaport Faculty of Medicine, Technion-lsrael Institute of Technology, Haifa, Israel.
Semin Arthritis Rheum. 2016 Feb;45(4):471-4. doi: 10.1016/j.semarthrit.2015.07.005. Epub 2015 Jul 21.
To evaluate the efficacy of colchicine in reducing the frequency of attacks in patients with PFAPA.
We conducted a 6-month open label, randomized, controlled study among patients with PFAPA who attend the Pediatric Rheumatology Clinic at the Rambam Medical Center in Israel. A total of 18 patients aged4 -11 years (males:females ratio = 11:7) were randomized into a control group (I, 10 children) and a study group (II, 8 children). Group I was followed for 6 months without any intervention, and group II was initially followed for 3 months and was thereafter treated with colchicine for 3 additional months, according to standard regimen. During the 6-month period of the study the patients and their physician recorded all the episodes of PFAPA in a constructed log. DNA analyses for the 5 common FMF mutations in Israel were performed in 17 out of the 18 patients.
The number of episodes during the first 3 months was similar in both groups (group I 3.2 ± 1.5, group II 4.9 ± 2.3; p ≤ 0.12). Group II had significantly less PFAPA attacks in the second period while on colchicine therapy (4.9 ± 2.3 vs. 1.6 ± 1.2; p ≤ 0.01), in opposition to group I, where no difference in the number of attacks was noted between the first and second period of follow-up (3.2 ± 1.5 vs. 2.7 ± 1.5; p = 0.33). Of the 17 patients tested, 8 were carriers for FMF mutations (2 in group I and 6 in group II).
Colchicine prophylaxis seems to be effective in reducing the number of attacks in PFAPA.
评估秋水仙碱在降低PFAPA患者发作频率方面的疗效。
我们在以色列兰巴姆医疗中心儿科风湿病诊所的PFAPA患者中进行了一项为期6个月的开放标签、随机对照研究。共有18名年龄在4至11岁的患者（男：女比例为11：7）被随机分为对照组（I组，10名儿童）和研究组（II组，8名儿童）。I组在无任何干预的情况下随访6个月，II组最初随访3个月，之后根据标准方案用秋水仙碱再治疗3个月。在研究的6个月期间，患者及其医生在构建的日志中记录了所有PFAPA发作情况。18名患者中的17名进行了以色列5种常见家族性地中海热（FMF）突变的DNA分析。
前3个月两组的发作次数相似（I组3.2±1.5，II组4.9±2.3；p≤0.12）。II组在接受秋水仙碱治疗的第二个时期PFAPA发作明显减少（4.9±2.3对1.6±1.2；p≤0.01），而I组在随访的第一和第二个时期发作次数无差异（3.2±1.5对2.7±1.5；p = 0.33）。在接受检测的17名患者中，8名是FMF突变携带者（I组2名，II组6名）。
秋水仙碱预防似乎对减少PFAPA发作次数有效。
